Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAR002
- Development stage
- Phase 2
- Lead developer
- Marea Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Unknown
01
Overview
MAR002 is a potential first-in-class anti-growth hormone receptor (GHR) monoclonal antibody being developed by Marea Therapeutics for the treatment of acromegaly. It acts as a GHR antagonist, blocking the activity of the growth hormone receptor, which is implicated in the pathophysiology of acromegaly—a disorder characterized by excessive growth hormone production. Preclinical studies suggest that MAR002 may inhibit inflammatory and neuropathic trigeminal pain and reduce neuronal activation in relevant models. The drug is currently in preclinical development, with no clinical trials yet reported as initiated or completed[1][3][4].
02
Targets
GHR (Growth hormone receptor)
Beyond the preview
Go deeper on MAR002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAR002.